Literature DB >> 30226168

External Quality Assessment for Zika Virus Molecular Diagnostic Testing, Brazil.

Sally A Baylis, Johannes Blümel.   

Abstract

Entities:  

Keywords:  NAAT; NAT; World Health Organization; Zika virus; armored RNA; controls; external quality assessment; inactivation; international standard; nucleic acid amplification technique; viruses

Mesh:

Year:  2018        PMID: 30226168      PMCID: PMC6154134          DOI: 10.3201/eid2410.180360

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Fischer et al. described an external quality assessment exercise for laboratories in Brazil that perform molecular testing for Zika virus and the development of an armored RNA control material (). Armored RNAs are RNA transcripts synthesized by in vitro transcription; they are encapsulated in a bacteriophage protein coat and are nuclease resistant. In addition to the external quality assessment samples, laboratories were sent vials of the World Health Organization (WHO) International Standard (IS) for Zika virus, which was prepared by using heat-inactivated virus (). Concentrations of WHO ISs are defined in IUs, in this case referring to the viral load, and, because of limitations on number of vials prepared in each batch, they are intended for calibrating secondary standards, including calibrators and run controls in IU facilitating comparison of assays (http://apps.who.int/medicinedocs/documents/s23325en/s23325en.pdf). Secondary standards, such as armored RNAs, traceable in IU (in accordance with ISO 17511:2003), are important complementary reagents to WHO ISs. However, the study by Fischer et al. was missing the calibration of the armored RNA in IU, which is essential for traceability. Because of packaging limitations of the protein coat, armored RNAs contain only partial genome sequences, compared with live or inactivated virus preparations such as the WHO ISs, which contain full-length genomes. Consequently, armored RNAs are restricted to controlling only certain assays. However, it may be easier to import armored RNAs into countries where disease outbreaks are occurring because they are noninfectious and have not been derived from either viremic plasma or cell culture–derived virus that has undergone heat inactivation. Inactivation protocols of viral stock materials must be validated on a case-by-case basis. Certain viruses, such as Zika virus, are heat labile (), whereas viruses such as alphaviruses are much more heat resistant, although there is a wide variation in susceptibility to heat inactivation between different members of the genus (,). The availability of controls, such as armored RNAs, is essential to ensure consistent assay performance on a daily basis and maintain stocks of WHO IS samples for calibration.
  5 in total

1.  Inactivation and removal of Zika virus during manufacture of plasma-derived medicinal products.

Authors:  Johannes Blümel; Didier Musso; Sebastian Teitz; Tomoyuki Miyabayashi; Klaus Boller; Barbara S Schnierle; Sally A Baylis
Journal:  Transfusion       Date:  2016-10-12       Impact factor: 3.157

2.  Virus-specific thermostability and heat inactivation profiles of alphaviruses.

Authors:  So Lee Park; Yan-Jang S Huang; Wei-Wen Hsu; Susan M Hettenbach; Stephen Higgs; Dana L Vanlandingham
Journal:  J Virol Methods       Date:  2016-04-11       Impact factor: 2.014

3.  Harmonization of nucleic acid testing for Zika virus: development of the 1st World Health Organization International Standard.

Authors:  Sally A Baylis; Kay-Martin O Hanschmann; Barbara S Schnierle; Jan-Hendrik Trösemeier; Johannes Blümel
Journal:  Transfusion       Date:  2017-02-23       Impact factor: 3.157

4.  Temperature Tolerance and Inactivation of Chikungunya Virus.

Authors:  Yan-Jang S Huang; Wei-Wen Hsu; Stephen Higgs; Dana L Vanlandingham
Journal:  Vector Borne Zoonotic Dis       Date:  2015-11       Impact factor: 2.133

5.  External Quality Assessment for Zika Virus Molecular Diagnostic Testing, Brazil.

Authors:  Carlo Fischer; Celia Pedroso; Alfredo Mendrone; Ana Maria Bispo de Filippis; Antonio Carlos Rosário Vallinoto; Bergmann Morais Ribeiro; Edison Luiz Durigon; Ernesto T A Marques; Gubio S Campos; Isabelle F T Viana; José Eduardo Levi; Luciano Cesar Scarpelli; Mauricio Lacerda Nogueira; Michele de Souza Bastos; Nathalia C Santiago Souza; Ricardo Khouri; Sanny Lira; Shirley Vasconcelos Komninakis; Cécile Baronti; Rémi N Charrel; Beate M Kümmerer; Christian Drosten; Carlos Brites; Xavier de Lamballerie; Matthias Niedrig; Eduardo Martins Netto; Jan Felix Drexler
Journal:  Emerg Infect Dis       Date:  2018-05-17       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.